Oculeve closes a $16.6 million equity funding round in supports of its flagship implantable technology, which stimulates the lacrimal glands in the eyes to spur natural tear production.
San Francisco startup Oculeve Inc. closed a $16.6 million funding round in supports of its implantable technology for treatment of dry eye disease.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1gQ0Jce
Cap comentari:
Publica un comentari a l'entrada